Publications by authors named "Eleonora Calabretta"

Claim this Profile
A
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.
Maria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, Matin Salehi, Federico Jauk, Eleonora Calabretta

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.
Edward Richardson, Clifton C Mo, Eleonora Calabretta, Francesco Corrado, Mehmet H Kocoglu

Biomolecules· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma.
Björn Chapuy, Timothy Wood, Chip Stewart, Andrew Dunford, Kirsty Wienand, Eleonora Calabretta

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment.
Vanessa Cristaldi, Lodovico Terzi di Bergamo, Lucrezia Patruno, Marinos Kallikourdis, Giada Andrea Cassanmagnago, Eleonora Calabretta

Front Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma.
Julia Paczkowska, Ming Tang, Kyle T Wright, Li Song, Kelsey Luu, Eleonora Calabretta

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control.
Annalisa Ruggeri, Francesco Corrado, Antonio Voza, Lee-Jen Wei, Gloria Catalano, Eleonora Calabretta

Haematologica· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.
Clifton C Mo, Edward Richardson, Eleonora Calabretta, Francesco Corrado, Mehmet H Kocoglu

Blood Rev· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.
Eleonora Calabretta, Martina di Trani, Francesco Corrado, Martina Sollini, Vanessa Cristaldi

Br J Haematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
Eleonora Calabretta, Anna Guidetti, Francesca Ricci, Martina Di Trani, Chiara Monfrini

Br J Haematol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.
Eleonora Calabretta, Mehdi Hamadani, Pier Luigi Zinzani, Paolo Caimi, Carmelo Carlo-Stella

Blood· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes.
Edward Richardson, David García-Bernal, Eleonora Calabretta, Rubén Jara, Marta Palomo

Expert Opin Ther Targets· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies.
Eleonora Calabretta, Jose M Moraleda, Massimo Iacobelli, Ruben Jara, Israel Vlodavsky

Br J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy.
Eleonora Calabretta, Carmelo Carlo-Stella

Cells· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.
Eleonora Calabretta, Francesco d'Amore, Carmelo Carlo-Stella

Int J Mol Sci· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis